首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
刘海涛  陶凌  李飞  孟欣  李剑  王琼  李伟杰 《心脏杂志》2016,28(5):579-580
正1对象和方法1.1对象患者男性,67岁,主因间歇性胸痛、气短、胸闷3个月入第四军医大学西京医院心脏外科,入院査体:体形明显消瘦,脉短绌,血压130/82mmH g(1 mmH g=0.133 k Pa),心率92次/min,率不齐,心率大于脉率,主动脉瓣听诊区可闻及4/6级收  相似文献   

2.
经导管主动脉瓣置入术(TAVI)从一诞生就备受关注,近几年已然成为介入心脏病学一颗璀璨“明星”。虽然不像前几年有PARTNER那样重磅级的研究公布,但2013年TAVI还是取得一定进展。本文拟回顾2013年TAVI主要研究进展,并对其前景做出展望。  相似文献   

3.
贺强  杨剑  易定华 《心脏杂志》2010,22(3):461-464
本文介绍了经导管介入治疗主动脉瓣狭窄的进展,主要就支架主动脉瓣的产品和手术入路的选择方面进行了总结和回顾。  相似文献   

4.
主动脉瓣狭窄是常见的心血管疾病,患者一旦出现临床症状,病情进展迅速。经导管主动脉瓣置入术作为治疗主动脉瓣狭窄的新兴介入技术,已在外科手术高危及禁忌人群中开展。因经导管主动脉瓣置入术为非直视手术,精确的影像学评估尤为重要。心脏磁共振具有高时间、空间分辨率和高组织对比度优势,该文介绍心脏磁共振不同序列在经导管主动脉瓣置入术中的应用。  相似文献   

5.
自2002年进行了世界上首例经导管主动脉瓣膜置换(transcatheter aortic valve implant,TAVI)治疗主动脉狭窄,世界各地的研究均表明:对于无法进行外科主动脉瓣膜置换(aortic valve replacement,AVR)或外科AVR手术存在高风险的患者,这项新技术是安全有效的。尽管进行TAVI手术的多为高风险患者,但手术成功后30 d生存率高于90%,  相似文献   

6.
经导管主动脉瓣置入手术自从2002年临床成功开展以来发展非常迅猛,各类技术更新层出不穷,输送器尺寸越来越小已经发展到14F,卒中比例小于4%,瓣周漏和起搏器的比例也随着临床技术经验和瓣膜产品设计更新而不断降低。而且在二叶畸形、重度钙化等领域置入技术也获得良好效果。中国经导管主动脉瓣置入手术起步较晚,但是自2017年自主知识产权瓣膜上市之后发展很快,2019年全国完成超过2000例手术,也组织发布了一些专家共识。另外一方面,国内大多数单位还处于起步阶段,经导管主动脉瓣置入手术的技术研究和推广尚待规范化的进行。  相似文献   

7.
主动脉瓣狭窄常见于高龄人群,患者出现临床症状未经治疗平均存活仅1~3年。外科主动脉瓣置换术是治疗主动脉瓣严重狭窄的传统方法,但患者多因高龄、伴左心室功能障碍或多种并发症而致死亡率明显增加[1]。  相似文献   

8.
2002年首例患者接受经导管主动脉瓣置换术(TAVI)以来,目前全球已有超过1万人从中获益。然而,TAVI术后可出现出血、血栓、心律失常、脑血管事件甚至死亡等许多并发症。尽管当前经验和技术均有所提高,围手术期及TAVI术后的缺血和出血并发症仍然普遍存在,并严重影响患者的预后。因此,权衡出血与血栓风险对指导接受TAVI手术患者的抗栓策略至关重要。但目前并无针对此问题的专家共识和推荐,相关指南的证据水平相对较低。本文对TAVI术后抗栓治疗的现有文献进行综述,旨在为临床诊疗及开展进一步研究提供思路。  相似文献   

9.
2002年,Cribier等[1]首先为一名有严重症状的主动脉瓣狭窄患者经导管置入Edwards人工瓣膜,开创了经导管主动脉瓣膜置入(transcatheter aortic valve implantation,TAVI)的新时代。2005年第一枚自膨胀的CoreValve置入患者体内。  相似文献   

10.
经导管主动脉瓣植入术(TAVI)可用于主动脉瓣严重狭窄需换瓣但传统开胸手术风险太大而难以实施的患者,第一个前瞻性大样本多中心的TAVI临床试验PARTNER研究已经完成.该研究显示,与药物治疗相比,经股动脉或经心尖途径植入Edwards-Sapien人工主动脉瓣膜,能显著降低患者的术后1年死亡率、改善预后并提高生活质量...  相似文献   

11.
12.
13.
经导管主动脉瓣中瓣植入术是生物瓣毁损后最理想的二次和多次干预手段之一,尤其适合于高危或不耐受手术患者。随着此类术式在国内外临床应用和报道的不断增加,新技术同样带来了新问题,如冠状动脉阻塞和术后跨瓣压差增高等,因此对其发生机制及处理最新进展加以综述就变得十分必要。  相似文献   

14.
15.
16.
AV Conduction After TAVI and SAVR . Introduction: Atrioventricular conduction abnormalities (AVCA) may complicate transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). The aim of this study was to prospectively evaluate AVCA after TAVI and SAVR. Methods and Results: Among 50 patients undergoing TAVI and 25 patients undergoing SAVR a continuous 7‐day Holter electrocardiogram (ECG) was recorded after the procedure. ECGs during TAVI and 12‐lead ECGs before and 1 and 7 days after TAVI and SAVR were analyzed. At baseline, TAVI patients were older (mean 82.1 vs 75.4, P < 0.001), had a longer PR interval (median 200 milliseconds vs 175 milliseconds, P = 0.004) and broader QRS width (median 100 milliseconds vs 80 milliseconds, P = 0.007) than SAVR patients. New AVCA were observed among 29 TAVI patients (58%), mostly new left bundle branch block (76%). Predilatation induced new AVCA in 14 TAVI patients (28%). New AVCA resolved within 24 hours in 15 TAVI patients (30%), and persisted in 14 TAVI (28%) and 3 SAVR patients (12%, P = 0.12). Among patients with persistent QRS width <120 milliseconds during the first 24 hours after TAVI, QRS width remained stable during the remainder of the observation period. During Holter monitoring complete AV block was observed in 4 TAVI patients (8%) and 3 SAVR patients (12%; P = 0.68). Conclusions: Almost half of AVCA during TAVI are induced by predilatation, but half of them resolve within 24 hours. Persistent AVCA are more frequently observed after TAVI than SAVR. If QRS width is below 120 milliseconds the first day after TAVI, the risk of late AVCA seems low. (J Cardiovasc Electrophysiol, Vol. 23 pp. 1115‐1122, October 2012)  相似文献   

17.
18.
Objectives:The aim of the present analysis is to compare the quantitative angiographic aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) among three balloon-expandable valves.Background:Quantitative videodensitometric aortography is an objective, accurate, and reproducible tool for adjudication of AR following TAVI.Methods:This is a retrospective corelab analysis, independent from industry, of aortograms from patients treated with TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., India), Sapien 3, and XT THVs (Edwards Lifesciences, Irvine, CA, USA). The study comprised of 108 analyzable aortograms from consecutive patients in a multicenter European registry who underwent Myval THV implantation. The results of quantitative assessment of AR in the Sapien 3 THV (n = 397) and Sapien XT THV (n = 239) were retrieved from a published pooled database.Results:The Myval THV had the lowest proportion of patients with moderate or severe angiographic quantitative AR (2.8%) compared to the Sapien 3 THV (8.3%; p = 0.049) and Sapien XT THV (10.9%; p = 0.012). Furthermore, the Myval THV had the lowest mean angiographic quantitative AR (6.3 ± 6.3%), followed by Sapien 3 THV (7.6 ± 7.1%) and Sapien XT THV (8.8 ± 7.5%), and it was significantly lower than that of the Sapien XT THV (p = 0.006), but not significantly different from Sapien 3 THV (p = 0.246).Conclusion:The Myval THV, in comparison with other BEV’s analyzed in our database, showed a lower occurrence of moderate or severe AR after TAVI. These results should be confirmed in prospective cohorts of randomized patients with head-to-head THV comparisons.  相似文献   

19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号